Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides

globenewswire.com
ABBV ADAG Adagene is mentioned as a key company in the immunotherapy sector, indicating its presence in the market without specific sentiment. ADAP ACET Adicet Bio is listed as a key company involved in cancer immunotherapy, indicating its participation in the market. ALXO ALX Oncology Holdings is mentioned as a key company in the immunotherapy sector, indicating its involvement without specific sentiment. AMBR Ambrx Biopharma is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. AMGN Amgen is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. RCUS Arcus Biosciences is listed as a key company in the cancer immunotherapy space, indicating its participation without specific sentiment. AZN AstraZeneca is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. ATRC Atreca is mentioned as a key company in the immunotherapy market, suggesting its role without explicit sentiment. BBLU BIIB Biogen Inc. is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. BNTX BioNTech is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. BOLT Bolt Biotherapeutics is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. BMY CRBU Caribou Biosciences is listed as a key company in the cancer immunotherapy space, indicating its participation without specific sentiment. CLDX Celldex Therapeutics is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. CRVS Corvus Pharmaceuticals is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. LLY EVAX Evaxion Biotech is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. GNSS Genenta Science is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. GILD Gilead Sciences is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. GLSI Greenwich LifeSciences is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. IMUX ImmunityBio is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. IMMX Immunocore Holdings is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. IMNM Immunome is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. INCY Incyte is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. INDP Indaptus Therapeutics is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. ISRL Instil Bio is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. IOBT Iovance Biotherapeutics is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. JNJ MRK Merck & Co. is mentioned for buying into a new kind of cancer immunotherapy, suggesting a positive strategic move and interest in the sector's growth. MRNA Moderna is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. MBIO Mustang Bio is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. NVS Novartis is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. NVX Novavax is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. PDSB PDS Biotechnology is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. PFE Pfizer is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. REGN Regeneron Pharmaceuticals is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. SNY Sanofi is listed as a key company in the immunotherapy sector, indicating its involvement in the market without specific sentiment. SNT Sensei Biotherapeutics is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. URGN UroGen Pharma is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment. ZYME Zymeworks is listed as a key company in the cancer immunotherapy market, suggesting its role without explicit sentiment.

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides" report has been added to ResearchAndMarkets.com's offering.

Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions, the global market is poised for dramatic growth. The impact on the health care industry is enormous. This report forecasts the market size out to 2027.

Use independent research that makes you the expert.Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1 Market Guides

1.1 Situation Analysis

1.2 Guide for Executives and Marketing Staff

1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

2.1 What is Cancer Immunotherapy?

2.2 Immunotherapy - the looming cures

2.3 Market Definition

2.4 Methodology

2.5 U.S. Medical Market and Pharmceutical Spending - Perspective

2.5.1 Global Expenditures for Medicines

3 Immunotherapy - Guide to Immune Technologies

3.1 The Immune System

3.1.1 Innate immune system

3.1.1.1 Surface barriers

3.1.1.2 Inflammation

3.1.1.3 Complement system

3.1.1.4 Cellular barriers

3.1.1.5 Natural killer cells

3.1.2 Adaptive immune system

3.1.2.1 Lymphocytes

3.1.2.2 Killer T cells

3.1.2.3 Helper T cells

3.1.2.4 Gamma delta T cells

3.1.2.5 B lymphocytes and antibodies

3.1.3 Tumor immunology - the immune surveillance system

3.2 Immuno Oncology Technologies

3.2.1 Monoclonal Antibodies

3.2.1.1 Outlook for Monoclonal Antibodies

3.2.1.2 Companies with Monoclonal Antibodies in their Pipeline

3.2.2 Cancer vaccines

3.2.2.1 Outlook for Cancer Vaccines

3.2.2.2 Companies with Cancer Vaccines in their Pipeline

3.2.3 Cytokines

3.2.3.1 Outlook for Cytokines

3.2.3.2 Companies with Cytokines in their Pipeline

3.2.4 Cell Based Therapies

3.2.4.1 Outlook for Cell Based Therapies

3.2.4.2 Companies with Cell Based Therapies in their Pipeline

3.2.5 Inhibitors/Agonists

3.2.5.1 Outlook for Inhibitors/Agonists

3.2.5.2 Companies with Inhibitors/Agonists in their Pipeline

3.2.6 Antibody Drug Conjugates

3.2.6.1 Outlook for Antibody Drug Conjugates

3.2.6.2 Companies with Antibody Drug Conjugates in their Pipeline

3.2.7 Others

3.2.7.1 Outlook for Other Therapeutics

3.2.7.2 Companies with Viral Therapeutics in their Pipeline

3.2.7.3 Companies with Other Therapeutics in their Pipeline

4 Industry Overview

4.1 Market Players - Roles & Impacts

4.1.1 Drug manufacturers - Larger/pharmaceutical

4.1.2 Drug manufacturers - Generic

4.1.3 Contract Research and Manufacturing

4.1.4 In Vitro Diagnostics Industry

4.1.5 Drug Marketing Companies

4.1.6 Biotechnology Companies

4.1.7 Regulatory Bodies

5 Market Trends

5.1 Factors Driving Growth

5.1.1 Outcome potential

5.1.2 Fast tracking

5.1.3 Funding

5.1.4 Technology Environment

5.1.5 Target Solutions

5.2 Factors Limiting Growth

5.2.1 Cost of Treatment

5.2.2 Clinical Trials Role

5.2.3 Combinations

5.2.4 Protocols

5.3 Therapeutic Technology Development

5.3.1 Combinations - Issues and Complexity

5.3.2 Preference for a drug

5.3.3 Problems of Immunity Engineering

5.3.4 The Role of Cost

5.3.5 The Disruption Dynamic

5.3.6 CAR-T Cell Therapy

5.3.7 The Next Five Years

6 Cancer Immunotherapy Recent Developments

6.1 Recent Developments - Importance and How to Use This Section

6.1.1 Importance of These Developments

6.1.2 How to Use This Section

6.2 Merck, buys into new kind of cancer immunotherapy

6.3 Immunotherapy after surgery

6.4 Anti-CTLA-4 nanobody a promising approach

6.5 Continued Success with Immunotherapy in Melanoma

6.6 AC Immune Receives FDA Fast Track Designation

6.7 LTZ Announces Financing

6.8 Immunotherapy for Cancer Overview

6.9 Implantable device shrinks pancreatic tumors

6.10 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence

6.11 Towards a Universal Cancer Immunotherapy

6.12 New Strategy May Improve T-Cell Therapy in Solid Tumors

6.13 Immunotherapy linked to increase in Medicare spending

6.14 Immunotherapy Effective with Ovarian Cancer

6.15 Cancer Immunotherapy Granted Fast Track

7 Profiles of Key Immunotherapy Companies

7.1 AbbVie

7.2 Achilles Therapeutics

7.3 Acumen Pharmaceuticals

7.4 Adagene

7.5 Adaptimmune Therapeutics

7.6 Adicet Bio

7.7 ALX Oncology Holdings

7.8 Ambrx Biopharma

7.9 Amgen

7.10 Apexigen

7.11 Arcus Biosciences

7.12 argenx

7.13 AstraZeneca

7.14 Atreca

7.15 Avalo Therapeutics

7.16 Avid Bioservices

7.17 Bavarian Nordic

7.18 BioAtla

7.19 Biogen Inc.

7.20 BioNTech

7.21 Bolt Biotherapeutics

7.22 Bristol-Myers Squibb

7.23 Candel Therapeutics

7.24 Caribou Biosciences

7.25 Celldex Therapeutics

7.26 Checkpoint Therapeutics

7.27 Chinook Therapeutics

7.28 Corvus Pharmaceuticals

7.29 Cullinan Oncology

7.30 Eli Lilly

7.31 EOM Pharmaceuticals

7.32 Evaxion Biotech

7.33 Genenta Science

7.34 Gilead Sciences

7.35 Gracell Biotechnologies

7.36 Greenwich LifeSciences

7.37 Gritstone bio

7.38 Harpoon Therapeutics

7.39 ImmunityBio

7.40 Immunocore Holdings

7.41 Immunome

7.42 IMV Inc

7.43 Incyte

7.44 Indaptus Therapeutics

7.45 Instil Bio

7.46 Iovance Biotherapeutics

7.47 Johnson & Johnson

7.48 Marker Therapeutics

7.49 Medicenna Therapeutics

7.50 Merck & Co.

7.51 Merus

7.52 Moderna

7.53 Mustang Bio

7.54 Nanobiotix

7.55 Neoleukin Therapeutics

7.56 Novartis

7.57 Novavax

7.58 Oncorus

7.59 PDS Biotechnology

7.60 Pfizer

7.61 Regeneron Pharmaceuticals

7.62 Roche

7.63 Sanofi

7.64 Sensei Biotherapeutics

7.65 Senti Biosciences

7.66 Surface Oncology

7.67 Takeda Pharmaceutical

7.68 TC Biopharm

7.69 ThermoGenesis Holdings

7.70 UroGen Pharma

7.71 Werewolf Therapeutics

7.72 Xilio Therapeutics

7.73 Zymeworks

8 The Global Market for Immuno-Oncology Therapeutics

8.1 Global Market Overview by Country

8.2 Global Market by Therapy - Overview

8.3 Global Market by Cancer - Overview

8.4 Global Market by Customer - Overview

9 Global Immuno-Oncology Therapy Markets - By Therapy

9.1 MAB

9.2 Cytokine

9.3 Vaccine

9.4 Cell Based

9.5 Inhibitor/Agonist

9.6 Other IO Therapy

10 Global Immuno-Oncology Therapeutic Markets - By Cancer

10.1 Breast

10.2 Colorectal

10.3 Cervical

10.4 Lung

10.5 Precancer

10.6 Prostate

10.7 Melanoma

10.8 Blood

10.9 Other Cancer

11 Global Immuno-Oncology Therapeutic Markets - By Customer

11.1 Pharma

11.2 Clinic

11.3 Other Customer

12 Appendices

12.1 FDA Cancer Drug Approvals by Year

12.2 Clinical Trials Started

12.3 Prevalence of Cancer Treatments

For more information about this report visit https://www.researchandmarkets.com/r/p21550

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.